US cattle herd at a 73-year low

The US is the world’s largest FBS producing country. In 2024, the US cattle inventory fell to its lowest level since 1951 — a direct result of sustained drought across major ranching states, high feed costs, and a multi-year herd liquidation cycle. Fewer animals mean fewer pregnant cows at slaughter and significantly less fetal blood available for serum collection. Industry analysts project that FBS production capacity from the US will remain constrained through at least 2028–2029 as herds rebuild.

Growing demand from biopharmaceuticals and cell therapy

At the same time, demand for FBS is increasing — driven by expansion in biologics manufacturing, vaccine production, cell therapy, and the rapid growth of mRNA and viral vector platforms. Labs that previously used modest FBS volumes are now running large-scale upstream bioprocesses with substantial serum requirements. Demand growth is outpacing what a shrinking herd can supply.

Distributor allocation cuts and lot fragmentation

As manufacturers face production constraints, they are prioritising direct customers with long-term supply agreements. Distributors purchasing on the spot market are facing allocation cuts, resulting in smaller available lot sizes, more frequent substitutions between origins, and less predictable lead times. Labs sourcing FBS through indirect channels are most exposed.

1. Validate a secondary supplier while your primary lot is still available

The worst time to start validating a new FBS supplier is when your current lot runs out. Begin a parallel validation now — request samples from a supplier with a different sourcing geography, run them through your standard cell culture validation protocol, and qualify the lot before you need it.

2. Switch from spot purchasing to lot reservation

Spot-market purchasing is high-risk in a shortage environment. Lot reservation — testing and reserving a specific lot before committing to a bulk order — allows you to lock in supply at validated specifications. Most professional serum suppliers offer this without pre-payment.

3. Build 3–6 months of buffer stock

FBS is stable at −20 °C for at least 24 months when handled correctly. In a constrained market, holding a validated reserve eliminates the risk of an unplanned supply gap disrupting active experiments or manufacturing campaigns.

4. Diversify origins — do not rely on a single geography

If your current validated FBS is US-only origin, qualify a South American or Australian origin now in parallel. Most well-characterised cell lines tolerate origin switching with a standard lot validation — you do not need to repeat full process development from scratch.

5. Consider whether any of your applications can transition to reduced-serum or alternative supplements

Not every application benefits from a full serum-free switch, but reducing FBS concentration from 10% to 5–8% in non-critical applications — or moving to human platelet lysate (hPL) for xeno-free human cell work — reduces your total FBS consumption and extends validated lot lifetimes.